PCMX ACTIVITY AGAINST COMMON ATHLETE's FOOT FUNGI IS NECESSARY
• By The Pink Sheet
PCMX ACTIVITY AGAINST COMMON ATHLETE's FOOT FUNGI IS NECESSARY for the ingredient to move from Category III to Category I, FDA told W.F. Young at a July 31 OTC feedback meeting. The agency noted that a study submitted by Young evaluated the drug's efficacy against T. tonsurans, which FDA staffer C. Carnot Evans characterized as a "highly unusual" cause of tinea pedis. "I think there is a consensus that in any kind of evaluation of antifungal products there should be a spectrum of organisms, particularly involving those that are well known and are recognized to be [in] a cause and effect relationship in tinea pedis," Evans asserted. He cited antifungal testing guidelines developed by FDA's Rx Dermatology Drugs Advisory Cmte. in June 1984 which state: "Since tinea rubrum is considered one of the most common organisms found in tinea pedis and one of the most difficult to erradicate, a significant number of the clinical cases in each study should be culture positive for T. rubrum at the initial visit." The meeting was held at the request of the company as a follow-up to a June 10 feedback letter from FDA. Commenting on Young's study, which found 46 of 53 (86.6%) of subjects yielding T. tonsurans fungal isolates from the feet, FDA stated in its letter that one published study "indicates that only 5% to 15% of pedal lesions yield T. tonsurans" ("The Pink Sheet" June 24, T&G-81. W. F. Young consultant Ronald Pinkerton, MD, University of Connecticut School of Medicine, suggested that mycology might be changing. "I don't know of any other clinical disease that doesn't have a changing etiology at the genesis of clinical expression over 30 years," Pinkerton said. Evans responded that the idea that the cause of tinea pedis is changing is "unsupportable." He said no other companies that have received antifungal approvals have had spectrums like those submitted by Young. Company consultant Richard Tilton, PhD, University of Connecticut School of Medicine, asked when the "last, naturally occuring, complete identification of the mycology of the pathogenesis of athlete's foot" was conducted. He commented: "I can well understand your desire to have the product tested against a range of organisms. What I cannot understand, ladies and gentlemen, is your inability, or your refusal, to recognize what I consider to be a valid mycological analysis of tinea pedis in the environment. It is mindful of five years ago when people began to see Kaposi's sarcoma [and said] 'I haven't seen Kaposi's sarcoma in 20 years, therefore it doesn't exist.'"
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
HHS and its agencies violated the law by swiftly implementing “sweeping and poorly thought-through directives that ordered the bulk removal of healthcare resources,” including FDA draft guidances on diversity action plans and sex differences in clinical trials, a federal court said.
The legislation expected to be signed by President Trump is a mixed bag for pharmaceutical manufacturers depending on their product mix and manufacturing situation.
Industry associations EFPIA, EUCOPE and EURORDIS have praised the European Commission’s newly launched life sciences strategy, which will see investment funnelled into improving the clinical trial ecosystem and supporting advanced therapy development.